You are here

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

TitleDolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
Publication TypeJournal Article
Year of Publication2018
AuthorsTaiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE
JournalClin Infect Dis
Volume66
Issue11
Pagination1794-1797
Date Published2018 May 17
ISSN1537-6591
Abstract

Clinical Trials Registration: NCT02263326.

DOI10.1093/cid/cix1131
Alternate JournalClin. Infect. Dis.
PubMed ID29293895
PubMed Central IDPMC5961309
Grant ListUM1 AI069432 / AI / NIAID NIH HHS / United States